Literature DB >> 20566830

Innate retroviral restriction by Apobec3 promotes antibody affinity maturation in vivo.

Mario L Santiago1, Robert L Benitez, Mauricio Montano, Kim J Hasenkrug, Warner C Greene.   

Abstract

Apobec3/Rfv3 is an innate immune factor that promotes the neutralizing Ab response against Friend retrovirus (FV) in infected mice. Based on its evolutionary relationship to activation-induced deaminase, Apobec3 might directly influence Ab class switching and affinity maturation independently of viral infection. Alternatively, the antiviral activity of Apobec3 may indirectly influence neutralizing Ab responses by reducing early FV-induced pathology in critical immune compartments. To distinguish between these possibilities, we immunized wild-type and Apobec3-deficient C57BL/6 (B6) mice with (4-hydroxy-3-nitrophenyl) acetyl (NP) hapten and evaluated the binding affinity of the resultant NP-specific Abs. These studies revealed similar affinity maturation of NP-specific IgG1 Abs between wild-type and Apobec3-deficient mice in the absence of FV infection. In contrast, hapten-specific Ab affinity maturation was significantly compromised in Apobec3-deficient mice infected with FV. In highly susceptible (B6 x A.BY)F(1) mice, the B6 Apobec3 gene protected multiple cell types in the bone marrow and spleen from acute FV infection, including erythroid, B, T, and myeloid cells. In addition, B6 Apobec3 deficiency was associated with elevated Ig levels, but decreased induction of splenic germinal center B cells and plasmablasts during acute FV infection. These data suggest that Apobec3 indirectly influences FV-specific neutralizing Ab responses by reducing virus-induced immune dysfunction. These findings raise the possibility that enabling Apobec3 activity during acute infection with human pathogenic retroviruses, such as HIV-1, may similarly facilitate stronger virus-specific neutralizing Ab responses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20566830      PMCID: PMC3024598          DOI: 10.4049/jimmunol.1001143

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  62 in total

1.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

2.  Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway.

Authors:  Andrew Mehle; Bettina Strack; Petronela Ancuta; Chengsheng Zhang; Mark McPike; Dana Gabuzda
Journal:  J Biol Chem       Date:  2003-12-13       Impact factor: 5.157

Review 3.  Extrafollicular antibody responses.

Authors:  Ian C M MacLennan; Kai-Michael Toellner; Adam F Cunningham; Karine Serre; Daniel M-Y Sze; Elina Zúñiga; Matthew C Cook; Carola G Vinuesa
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

4.  The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.

Authors:  Silvestro G Conticello; Reuben S Harris; Michael S Neuberger
Journal:  Curr Biol       Date:  2003-11-11       Impact factor: 10.834

5.  Estimation of the relative affinity of B cell receptor by flow cytometry.

Authors:  Takeyuki Shimizu; Masayuki Oda; Takachika Azuma
Journal:  J Immunol Methods       Date:  2003-05-01       Impact factor: 2.303

6.  The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.

Authors:  Hui Zhang; Bin Yang; Roger J Pomerantz; Chune Zhang; Shyamala C Arunachalam; Ling Gao
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

7.  Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.

Authors:  Bastien Mangeat; Priscilla Turelli; Gersende Caron; Marc Friedli; Luc Perrin; Didier Trono
Journal:  Nature       Date:  2003-05-28       Impact factor: 49.962

8.  HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.

Authors:  Mariana Marin; Kristine M Rose; Susan L Kozak; David Kabat
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

9.  HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.

Authors:  Kim Stopak; Carlos de Noronha; Wes Yonemoto; Warner C Greene
Journal:  Mol Cell       Date:  2003-09       Impact factor: 17.970

10.  The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.

Authors:  Ann M Sheehy; Nathan C Gaddis; Michael H Malim
Journal:  Nat Med       Date:  2003-10-05       Impact factor: 53.440

View more
  24 in total

1.  Requirement for Fc effector mechanisms in the APOBEC3/Rfv3-dependent neutralizing antibody response.

Authors:  Kalani Halemano; Bradley S Barrett; Karl J Heilman; Thomas E Morrison; Mario L Santiago
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

2.  Murine Leukemia Virus P50 Protein Counteracts APOBEC3 by Blocking Its Packaging.

Authors:  Wenming Zhao; Charbel Akkawi; Marylène Mougel; Susan R Ross
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

3.  Persistent Friend virus replication and disease in Apobec3-deficient mice expressing functional B-cell-activating factor receptor.

Authors:  Mario L Santiago; Diana S Smith; Bradley S Barrett; Mauricio Montano; Robert L Benitez; Roberta Pelanda; Kim J Hasenkrug; Warner C Greene
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

Review 4.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

5.  APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription.

Authors:  Alyssa L MacMillan; Rahul M Kohli; Susan R Ross
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

Review 7.  Humoral immunity in the Friend retrovirus infection model.

Authors:  Kalani Halemano; Michael S Harper; Kejun Guo; Sam X Li; Karl J Heilman; Bradley S Barrett; Mario L Santiago
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

8.  Ribonuclease L is not critical for innate restriction and adaptive immunity against Friend retrovirus infection.

Authors:  Sam X Li; Bradley S Barrett; Michael S Harper; Karl J Heilman; Kalani Halemano; Amanda K Steele; Kejun Guo; Robert H Silverman; Mario L Santiago
Journal:  Virology       Date:  2013-05-29       Impact factor: 3.616

9.  Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection.

Authors:  Kalani Halemano; Kejun Guo; Karl J Heilman; Bradley S Barrett; Diana S Smith; Kim J Hasenkrug; Mario L Santiago
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-12       Impact factor: 11.205

10.  Negative impact of IFN-γ on early host immune responses to retroviral infection.

Authors:  Amanda K Duley; Mickaël J-Y Ploquin; Urszula Eksmond; Christoph G Ammann; Ronald J Messer; Lara Myers; Kim J Hasenkrug; George Kassiotis
Journal:  J Immunol       Date:  2012-07-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.